Yazar "Monzur, Farah" seçeneğine göre listele

Listeleniyor 1 - 6 / 6
  • Küçük Resim Yok
    Öğe
    Efficacy and Safety of Adalimumab in Inducing Clinical Remission in Crohn's Disease: A Meta-Analysis With Subgroup Analysis
    (Lippincott Williams & Wilkins, 2023) Aksan, Feyzullah; Tanriverdi, Lokman Hekim; Monzur, Farah
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    Efficacy and Safety of Adalimumab in Inducing Clinical Remission in Crohn's Disease: A Meta-Analysis With Subgroup Analysis
    (Lippincott Williams & Wilkins, 2023) Aksan, Feyzullah; Tanriverdi, Lokman Hekim; Monzur, Farah
    [No abstract available]
  • Küçük Resim Yok
    Öğe
    Glucagon-like peptide-1 receptor agonists associated with improved clinical outcomes in patients with inflammatory bowel disease: a retrospective cohort study
    (Springer, 2025) Aksan, Feyzullah; Abboud, Alan; Tanriverdi, Lokman H.; Aroniadis, Olga C.; Monzur, Farah
    Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated anti-inflammatory effects in preclinical models of inflammatory bowel disease (IBD), yet clinical data remain limited. This study aimed to assess the association between GLP-1 RAs exposure and disease-related outcomes, treatment patterns, and healthcare utilization in patients with IBD. We conducted a retrospective, propensity score-matched cohort study using data from the TriNetX Analytics Research Network. Adults diagnosed with Crohn's disease or ulcerative colitis between 2006 and 2022 were matched 1:1 based on GLP-1 RAs exposure. Patients with confounding comorbidities were excluded. Key outcomes included 5-year mortality, IBD-related surgeries and complications, medication use, and healthcare utilization. A total of 11,016 matched IBD patients were included (GLP-1 RAs: n = 5508; no GLP-1 RAs: n = 5508). Exposure to GLP-1 RAs was associated with a significantly lower 5-year mortality rate (8.05% vs 10.03%, hazard ratio [HR] 0.65, 95% confidence interval [CI] 0.54-0.78, p < 0.0001). Rates of IBD-related surgeries (HR 0.53, 95% CI 0.39-0.72) and complications (HR 0.81, 95% CI 0.70-0.93) were also reduced. Moreover, patients in the GLP-1 RAs group experienced fewer overall healthcare encounters (chi(2) = 136.52, p < 0.0001). Significant differences were observed in corticosteroid (p < 0.0001) and advanced biologic use (p < 0.0001), although rank biserial correlation was small (0.04 and - 0.11, respectively), and findings on medication use did not persist in subgroup analyses of ulcerative colitis and Crohn's disease patients. Our findings suggest a potential disease-modifying effect of GLP-1 RAs beyond glycemic control, especially in reducing mortality, complications, surgeries, and healthcare use. However, the clinical relevance of reduced medication use warrants further investigation through prospective trials.
  • Küçük Resim Yok
    Öğe
    Ozanimod for Induction and Maintenance of Remission in Ulcerative Colitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    (Lippincott Williams & Wilkins, 2023) Aksan, Feyzullah; Tanriverdi, Lokman Hekim; Monzur, Farah
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    Ozanimod for Induction and Maintenance of Remission in Ulcerative Colitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    (Lippincott Williams & Wilkins, 2023) Aksan, Feyzullah; Tanriverdi, Lokman Hekim; Monzur, Farah
    [No abstract available]
  • Küçük Resim Yok
    Öğe
    S1P Receptor Modulators Improve Clinical Outcomes in Ulcerative Colitis
    (Lippincott Williams and Wilkins, 2025) Tanriverdi, Lokman H.; Aksan, Feyzullah; Aroniadis, Olga; Monzur, Farah
    Objectives: – This systematic review and meta-analysis aimed to evaluate the efficacy and safety of sphingosine-1-phosphate (S1P) receptor modulators for achieving clinical remission and key outcomes in inflammatory bowel disease (IBD) patients and to examine the influence of baseline characteristics. Methods: – MEDLINE (Ovid), PubMed, Web of Science, and Cochrane CENTRAL were searched until January 1, 2024. Randomized controlled trials (RCTs) evaluating S1P receptor modulators in adult IBD patients were included. Meta-analyses used inverse variance random-effects models, with stratified analyses by disease type, prior anti-TNF use, corticosteroid use, disease location, and baseline Mayo score. Results: – Six RCTs involving 1744 patients (male: 58.8%; age: 41.1±13.5 y) were analyzed. S1P modulators significantly improved clinical remission versus placebo in induction (RR: 2.22; 95% CI: 1.30-3.80) and maintenance phases (RR: 2.79; 95% CI: 1.72-4.54). For UC patients, induction remission was notably higher with S1P modulators (RR: 2.69; 95% CI: 1.98-3.65). Stratified analyses indicated consistent efficacy across disease location (P=0.15), corticosteroid use (P=0.20), and Mayo scores (P=0.53). Prior anti-TNF-naive patients experienced greater benefits (P=0.04). Maintenance-phase remission rates favored etrasimod (RR: 4.26; 95% CI: 2.36-7.69) over ozanimod (RR: 2.09; 95% CI: 1.54-2.84; P=0.035). Secondary outcomes, including clinical response, endoscopic and histologic remission, mucosal healing, and corticosteroid-free remission, were also significantly improved. Overall, adverse events were more frequent with S1P modulators (RR: 1.18; 95% CI: 1.07-1.30); serious adverse events, infections, mortality, and cardiac events were comparable. Conclusions: – S1P modulators improved remission rates and secondary outcomes in UC with a generally favorable safety profile. More data on CD are needed. © 2025